This board has been quiet...

Quote






anonymous said:
Not much activity here recently. Have things improved at Romark or is it the same old sh!tstorm?
Click to expand...
I tend to find the pharma companies with the least activity on cafepharma are those who have the least to complain about (with the exception of company size, of course).
This is a good thing. Seems most people are happy which is why I accepted the job.
 






anonymous said:
Not much activity here recently. Have things improved at Romark or is it the same old sh!tstorm?
Click to expand...

Quiet no more: just released in journal “Nature”:

Nitazoxanide, a commercial antiprotozoal agent with an antiviral potential against a broad range of viruses including human and animal coronaviruses, inhibited the 2019-nCoV at a low-micromolar concentration (EC50 = 2.12 μM; CC50 > 35.53 μM; SI > 16.76). Further in vivo evaluation of this drug against 2019-nCoV infection is recommended.
 


















Well, Gilead’s Remdesivir literally brought the Seattle patient back from the dead, but Gilead is using most of its stock in the China trial. So, availability is going to be a problem. Also, these drugs must be given in a cocktail or resistance develops. So, probably three MOA’s would be best.

I know that chloroquine was part of one trial.
 






anonymous said:
Well, Gilead’s Remdesivir literally brought the Seattle patient back from the dead, but Gilead is using most of its stock in the China trial. So, availability is going to be a problem. Also, these drugs must be given in a cocktail or resistance develops. So, probably three MOA’s would be best.

I know that chloroquine was part of one trial.[/


https://www.nature.com/articles/s41422-020-0282-0
Click to expand...
 






Top Bottom
Back
Quote